Jacob P. Laubach

ScholarGPS® ID: 13110940470360

Affiliation

Dana-Farber Cancer Institute, Boston, United States

Affiliation History

Field

Medicine

Discipline

Oncology

Top Specialties

Metrics Summary

Publication Count

289

Predicted Citations

16,572

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial (journal article) O'Donnell, Elizabeth \| Mo, Clifton \| Yee, Andrew J \| Nadeem, Omar \| Laubach, Jacob \| Rosenblatt, Jacalyn \| Munshi, Nikhil \| Midha, Shonali \| Cirstea, Diana \| Chrysafi, Pavlina \| ... \| Raje, Noopur The Lancet Haematology, volume 11, issue 6, pages e415-e424 (2024). 10.1016/S2352-3026(24)00070-X Cited by (3) \| Cite \| Source
Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma (journal article) Hartley-Brown, Monique A. \| Mo, Clifton C. \| Nadeem, Omar \| Midha, Shonali \| Laubach, Jacob P. \| Richardson, Paul G. Cancers, volume 16, issue 6, pages 1166- (2024). 10.3390/cancers16061166 Cite \| Source
Clinical Outcomes of Monoclonal Gammopathy of Renal Significance Without Detectable Clones (journal article) Terashita, Maho \| Selamet, Umut \| Midha, Shonali \| Nadeem, Omar \| Laubach, Jacob \| Rennke, Helmut G. \| Murakami, Naoka Kidney International Reports, volume 8, issue 12, pages 2765-2777 (2023). 10.1016/j.ekir.2023.09.022 Cited by (1) \| Cite \| Source
Venetoclax in Combination with Daratumumab and Dexamethasone Elicits Deep, Durable Responses in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma: Updated Analyses of Minimal Residual Disease Negativity in Phase 1/2 Study (journal article) Bahlis, Nizar J \| Quach, Hang \| Baz, Rachid \| Vangsted, Annette J. \| Ho, Shir-Jing \| Abildgaard, Niels \| Laubach, Jacob \| Ribrag, Vincent \| Voorhees, Peter M. \| Wang, Xifeng \| ... \| Kaufman, Jonathan L. Blood, volume 142, issue Supplement 1, pages 338-338 (2023). 10.1182/blood-2023-180766 Cited by (1) \| Cite \| Source
A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) (journal article) O'Donnell, Elizabeth K. \| Mo, Clifton C. \| Yee, Andrew J. \| Nadeem, Omar \| Branagan, Andrew R. \| Laubach, Jacob \| Rosenblatt, Jacalyn \| Horick, Nora \| Richardson, Paul G. \| Raje, Noopur \| Cirstea, Diana Blood, volume 142, issue Supplement 1, pages 4671-4671 (2023). 10.1182/blood-2023-181019 Cited by (2) \| Cite \| Source
Ibrutinib in Combination with Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma (AFT-15) (journal article) Efebera, Yvonne \| Suman, Vera Jean \| Dinner, Shira N. \| Rosko, Ashley E \| Mckay, John T \| Barth, Peter \| Hagen, Patrick \| Usmani, Saad Z \| Richardson, Paul G. \| Laubach, Jacob P. Blood, volume 142, issue Supplement 1, pages 3340-3340 (2023). 10.1182/blood-2023-187296 Cite \| Source
A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma (journal article) Midha, Shonali \| Hartley-Brown, Monique A. \| Mo, Clifton C. \| Hossain, Shahrier \| Nadeem, Omar \| O’Donnell, Elizabeth K. \| Bianchi, Giada \| Sperling, Adam S. \| Laubach, Jacob P. \| Richardson, Paul G. Expert Opinion on Drug Safety, volume 22, issue 11, pages 1049-1071 (2023). 10.1080/14740338.2023.2274420 Cited by (3) \| Cite \| Source
P-099 Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma (journal article) Nadeem, Omar \| Redd, Robert \| Mo, Clifton \| Laubach, Jacob \| Richardson, Paul G. \| Prescott, Julia \| Marto, Marjorie \| Davie, Christine \| Ricciardi, Caroline \| Murphy, Elizabeth \| ... \| Ghobrial, Irene M. Clinical Lymphoma Myeloma and Leukemia, volume 23 (2023). 10.1016/S2152-2650(23)01717-2 Cite \| Source
P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma (journal article) Kaufman, Jonathan \| Quach, Hang \| Baz, Rachid \| Vangsted, Annette Juul \| Ho, Shir-Jing \| Abildgaard, Niels \| Laubach, Jacob \| Ribrag, Vincent \| Gibbs, Simon \| Medvedova, Eva \| ... \| Bahlis, Nizar Clinical Lymphoma Myeloma and Leukemia, volume 23 (2023). 10.1016/S2152-2650(23)01895-5 Cite \| Source
P-036 Real world single center expeirence of long-term toxicities with anti-BCMA CAR T-cell therapy in relapsed and refractory multiple myeloma (journal article) Costello, Patrick \| Laubach, Jacob \| Mo, Clifton \| Sperling, Adam \| Nikiforow, Sarah \| Redd, Robert \| Ramsdell, Linda \| Finn, Kathleen \| Desnoyers, Lauren \| Denisco, Michelle \| ... \| Midha, Shonali Clinical Lymphoma Myeloma and Leukemia, volume 23 (2023). 10.1016/S2152-2650(23)01654-3 Cite \| Source
P-035 Real world experience of patients treated with teclistamab: a BCMA-directed bispecific T-cell engaging therapy for multiple myeloma (journal article) Midha, Shonali \| Leblebjian, Houry \| Laubach, Jacob \| Mo, Clifton \| Sperling, Adam \| Nadeem, Omar \| Bianchi, Giada \| Hartley-Brown, Monique \| Ramsdell, Linda \| Donadio, Kristen \| ... \| Munshi, Nikhil Clinical Lymphoma Myeloma and Leukemia, volume 23 (2023). 10.1016/S2152-2650(23)01653-1 Cited by (2) \| Cite \| Source
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma (journal article) Richardson, Paul G. \| Durie, Brian G. \| Rosiñol, Laura \| Mateos, Maria-Victoria \| Dispenzieri, Angela \| Moreau, Philippe \| Kumar, Shaji \| Raje, Noopur \| Munshi, Nikhil \| Laubach, Jacob P. \| ... \| Anderson, Kenneth C. Haematologica, volume 108, issue 11, pages 2894-2912 (2023). 10.3324/haematol.2022.282624 Cited by (2) \| Cite \| Source
Selinexor: Targeting a novel pathway in multiple myeloma (journal article) Mo, Clifton C. \| Yee, Andrew J. \| Midha, Shonali \| Hartley‐Brown, Monique A. \| Nadeem, Omar \| O'Donnell, Elizabeth K. \| Bianchi, Giada \| Sperling, Adam S. \| Laubach, Jacob P. \| Richardson, Paul G. eJHaem, volume 4, issue 3, pages 792-810 (2023). 10.1002/jha2.709 Cited by (6) \| Cite \| Source
Monoclonal Gammopathy of Renal Significance (MGRS) Without Detectable Clones: Clinical Treatment Dilemma (journal article) Terashita, Maho \| Selamet, Umut \| Midha, Shonali \| Nadeem, Omar \| Laubach, Jacob \| Rennke, Helmut G. \| Murakami, Naoka Journal of the American Society of Nephrology, volume 34, issue 11S, pages 777-777 (2023). 10.1681/ASN.20233411S1777b Cite \| Source
A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial) (journal article) O'Donnell, Elizabeth K. \| Mo, Clifton C \| Nadeem, Omar \| Yee, Andrew J. \| Branagan, Andrew R. \| Laubach, Jacob \| Gammon, Marilyn T. \| Lively, Kathleen J. \| Packer, Lisette \| Harrington, Cynthia C. \| ... \| Raje, Noopur Blood, volume 140, issue Supplement 1, pages 7282-7283 (2022). 10.1182/blood-2022-156328 Cited by (2) \| Cite \| Source
Keeping an Eye on Belantamab: Characterizing Ocular Toxicities (journal article) Hossain, Shahrier \| Marzouk, Omar \| Leblebjian, Houry \| Redd, Robert A. \| Laubach, Jacob Blood, volume 140, issue Supplement 1, pages 13206-13207 (2022). 10.1182/blood-2022-166720 Cite \| Source
Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma (journal article) O’Donnell, Elizabeth K. \| Shapiro, Yael N. \| Yee, Andrew J. \| Nadeem, Omar \| Laubach, Jacob P. \| Branagan, Andrew R. \| Anderson, Kenneth C. \| Mo, Clifton C. \| Munshi, Nikhil C. \| Ghobrial, Irene M. \| ... \| El-Jawahri, Areej Blood Advances, volume 6, issue 17, pages 4967-4974 (2022). 10.1182/bloodadvances.2022007127 Cited by (11) \| Cite \| Source
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma (journal article) Ho, Matthew \| Moscvin, Maria \| Low, Soon Khai \| Evans, Benjamin \| Close, Sara \| Schlossman, Robert \| Laubach, Jacob \| Prada, Claudia Paba \| Glotzbecker, Brett \| Richardson, Paul G. \| Bianchi, Giada Leukemia & Lymphoma, volume 63, issue 10, pages 2403-2412 (2022). 10.1080/10428194.2022.2084729 Cited by (4) \| Cite \| Source
P-042: Phase 1 dose-escalation study of sotatercept in combination with lenalidomide and dexamethasone or pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (journal article) Yee, Andrew \| Laubach, Jacob \| Nooka, Ajay \| O’Donnell, Elizabeth \| Harrington, Cynthia \| Agyemang, Emerentia \| Burke, Jill \| Gammon, Marilyn \| Lively, Kathleen \| Packer, Lisette \| ... \| Raje, Noopur Clinical Lymphoma Myeloma and Leukemia, volume 22 (2022). 10.1016/S2152-2650(22)00372-X Cite \| Source
P-006: Real world experience of patients treated with idecabtagene vicleucel: a BCMA-directed chimeric antigen receptor T-cell therapy for multiple myeloma (journal article) Canonico, Dalton \| Laubach, Jacob \| Mo, Clifton \| Sperling, Adam \| Nikiforow, Sarah \| Redd, Robert \| Ramsdell, Linda \| McDermott, Kathleen \| Finn, Kathleen \| Desnoyers, Lauren \| ... \| Nadeem, Omar Clinical Lymphoma Myeloma and Leukemia, volume 22 (2022). 10.1016/S2152-2650(22)00336-6 Cite \| Source